article thumbnail

Specialised Therapeutics partners with Treeway to license ALS drug

Pharmaceutical Technology

Specialised Therapeutics has entered into a licensing agreement with Treeway for TW001, designed for treating amyotrophic lateral sclerosis.

Licensing 246
article thumbnail

IMIDomics to license TNAX’s drug candidate for IMIDs

Pharmaceutical Technology

IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).

Licensing 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Coeptis licenses Deverra Therapeutics’ clinical stage assets

Pharmaceutical Technology

Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

Licensing 130
article thumbnail

Reset Pharma partners with Filament to license psilocybin drug

Pharmaceutical Technology

Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.

Licensing 130
article thumbnail

uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS

Pharmaceutical Technology

Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1). The post uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS appeared first on Pharmaceutical Technology.

article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Licensing 305
article thumbnail

Renaissance to in-license St Jude’s humanised monoclonal antibody

Pharmaceutical Technology

Renaissance Pharma has signed an agreement to in-license St Jude Children’s Research Hospital’s Hu14.18K322A (Hu14.18).

Licensing 130